RxDoctor Payments Data

Brittain Heindl, MD

Cardiovascular Disease · Huntsville, ALNPI 1144587270

Payments from drug & device makers

$1,072in general payments, 2019–2025

Across 31 payments — averaging $34.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$188
  • Actelion Pharmaceuticals US, Inc.$125
  • AstraZeneca$118
  • Merck$107
  • Novo Nordisk$106
  • Cleerly, Inc.$104
  • plus $324 from 8 others

What the payments were for

  • Food & beverage$1,072100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,072 in reported general payments places this provider in the 25th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$301,872
Medicare patients
887
Services billed
11,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban363$315,199
FarxigaDapagliflozin Propanediol288$279,838
EntrestoSacubitril/Valsartan236$262,053
JardianceEmpagliflozin255$257,471
OzempicSemaglutide86$87,389
XareltoRivaroxaban45$30,624
Repatha SureclickEvolocumab28$19,548
Varenicline Tartrate44$19,504
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med266$13,110
MounjaroTirzepatide12$12,624
Atorvastatin Calcium845$10,561
Praluent PenAlirocumab15$10,020
VascepaIcosapent Ethyl11$7,998
Rosuvastatin Calcium453$7,370
Metoprolol Succinate526$6,639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$75$315,199363 claims
AstraZenecaFarxiga$118$279,838288 claims
NovartisEntresto$51$262,053236 claims
Novo NordiskOzempic$106$87,38986 claims
Esperion Therapeutics, Inc.Nexletol$15$5,70312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →